Why modular designs will be the future of advanced therapy manufacturing
Companies need to pay close attention to how they build out their advanced therapy medicinal products (ATMP) delivery supply chains. Autologous treatments require individual cell harvesting and a manufacturing cycle that begins and ends with the patient. Allogeneic therapies are also developed from human cells but are donor-derived and manipulated to treat groups of patients. Patients’ direct involvement, as well as the steps in both autologous and allogeneic production methods, insert operational risk into manufacturing that can affect commercial viability.
To minimize these risks, ATMP developers need appropriate cleanroom environments that achieve processing and regulatory objectives. Learn how AES Clean Technology delivers innovative modular cleanroom designs for advanced therapy manufacturing.